rs660339 — UCP2 Ala55Val

The Mitochondrial Efficiency Variant: When Less Uncoupling Means More Fat

Deep in your white fat cells, mitochondria constantly balance two competing demands: making ATP to power cellular work and dissipating energy as heat through a process called uncoupling¹¹ uncoupling
Proton leak across the inner mitochondrial membrane that bypasses ATP synthase, converting electrochemical energy to heat rather than ATP. UCP2 — uncoupling protein 2 — sits in the inner mitochondrial membrane and regulates this balance. It is expressed broadly across white adipose tissue, skeletal muscle, immune cells, and the pancreatic beta-cell. The Ala55Val variant (rs660339) replaces a small alanine with a bulkier valine at amino acid 55, subtly altering the protein's proton channel geometry and reducing the degree of uncoupling — with consequences for energy expenditure, fat storage, and metabolic risk.

The Mechanism

The Ala-to-Val substitution at position 55 lies within a functionally critical region of the UCP2 transmembrane domain. Val is a larger, more hydrophobic amino acid than Ala; structural models suggest this substitution partially occludes the proton channel, reducing the rate at which protons can re-enter the mitochondrial matrix via UCP2. The result is a higher mitochondrial membrane potential²² higher mitochondrial membrane potential
More electrochemical gradient preserved across the inner membrane, paradoxically increasing ATP yield per unit of fuel burned — the thermodynamic definition of greater metabolic efficiency.

Higher metabolic efficiency sounds advantageous, but in the context of energy balance it works against weight maintenance. When every calorie extracted from food yields slightly more ATP and slightly less heat, the body has fewer spontaneous energy losses. Val/Val individuals burn less fuel for the same level of physical output. In pancreatic beta-cells, UCP2 normally dampens ROS production and modulates glucose sensing; altered UCP2 activity in beta-cells changes the acute insulin response to glucose³³ acute insulin response to glucose
The first-phase insulin spike within 10 minutes of glucose challenge, measured by IVGTT.

The Evidence

The most direct evidence comes from a 1999 metabolic ward study⁴⁴ 1999 metabolic ward study
Astrup et al. Int J Obes 1999; 60 healthy volunteers, 24-hour indirect calorimetry in a respiratory chamber that measured 24-hour energy expenditure in all three genotypes. Val/Val individuals expended 311 kJ/day less than Ala/Ala and Ala/Val individuals (95% CI 24–598 kJ/day, p=0.03) after adjusting for fat-free mass, fat mass, and spontaneous physical activity. Val/Val also showed higher 24-hour respiratory quotient — a direct measure of reduced fat oxidation. Over a year, a 311 kJ/day deficit in expenditure corresponds to approximately 3–4 kg of additional fat accumulation if intake remains constant.

Population studies support this thermodynamic prediction. A Spanish cohort of 2,367 individuals⁵⁵ A Spanish cohort of 2,367 individuals
Gonzalez-Sanchez et al. 2011; Hortega and Pizarra studies found the Val/Val (TT in coding-strand notation) genotype was significantly associated with higher waist circumference and central adiposity. In Mexican patients with premature coronary artery disease, Val/Val carriers had elevated visceral abdominal fat, reduced subcutaneous fat, and a higher visceral-to-subcutaneous ratio⁶⁶ Val/Val carriers had elevated visceral abdominal fat, reduced subcutaneous fat, and a higher visceral-to-subcutaneous ratio
Gonzalez et al. 2018, n=1,706 (948 pCAD + 763 controls) — the most metabolically harmful fat distribution pattern.

Diabetes associations are less consistent. The CARDIA study⁷⁷ CARDIA study
Shuldiner et al. 2005; longitudinal cohort, predominantly African Americans and European Americans found Val/Val individuals had higher diabetes incidence over 15 years (5.8% vs 3.3% for Ala/Ala, p=0.02). A meta-analysis found a positive association under a dominant model (OR 1.27, 95% CI 1.03–1.57), with the association remaining significant only in Asian populations after stratification. However, the large ARIC study⁸⁸ ARIC study
Wang et al. 2008; n=12,056, 9-year prospective follow-up found no association with incident diabetes (HR 1.00 for Val/Val vs Ala/Ala), highlighting important population-specific and gene-environment interactions.

An intriguing counterpoint: in athletic contexts, Val/Val carriers show higher exercise efficiency and aerobic performance capacity⁹⁹ exercise efficiency and aerobic performance capacity
Overrepresented among elite endurance athletes; higher gross exercise efficiency at 40% VO2max (15.3% vs 13.5%). The same metabolic efficiency that predisposes to fat accumulation at rest becomes advantageous during sustained aerobic effort — less fuel burned per unit of mechanical work. This distinction between resting and exercise metabolic efficiency is clinically relevant when counseling Val/Val individuals.

Practical Actions

The Val/Val (AA on plus strand) individual's primary challenge is a structural reduction in resting energy expenditure — approximately 311 kJ/day that accumulates invisibly unless counteracted. Caloric deficit strategies must account for this: the same dietary prescription will produce less weight loss in Val/Val than in Ala/Ala individuals. Precision in caloric tracking matters more for this genotype.

Fat distribution is the more worrisome phenotype than absolute weight. Val/Val individuals tend to accumulate visceral rather than subcutaneous fat even at similar BMIs — measuring waist circumference alongside body weight is more informative. Visceral fat is metabolically active and drives insulin resistance, dyslipidemia, and cardiovascular risk independently of total adiposity.

Because Val/Val individuals show higher exercise efficiency (paradoxically, they extract more mechanical work per calorie), higher exercise volumes are needed to achieve equivalent energy expenditure. Two Val/Val individuals exercising at the same intensity as Ala/Ala individuals will burn fewer calories per session — duration and frequency compensate for this.

Interactions

rs660339 exists in a region of moderate linkage disequilibrium with the UCP2 promoter variant rs659366¹⁰¹⁰ rs659366
The -866G/A promoter polymorphism that regulates UCP2 transcription; r² ≈ 0.63–0.88 depending on population (-866G/A). These two variants often co-segregate, and haplotype analyses suggest their effects on obesity, visceral fat distribution, and metabolic parameters may be partially independent and potentially additive. Individuals carrying both the rs660339 AA genotype and the rs659366 AA genotype in the Spanish cohort showed the greatest central fat accumulation. Compound actions for this interaction should be developed when rs659366 is profiled.